ArticleMolecular therapy : the journal of the American Society of Gene Therapy2025
Correction of VWF multimerization in type 2A/IIC von Willebrand disease by exogenous VWF propeptide supplementation.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Novel therapies for von Willebrand disease.Blood advances · 2026Review
- Expression of wild-type and recombinant D4-CK domains of VWF gene with novel variants in Pakistan.Molecular biology reports · 2026Article
- Restoring VWF multimerization via endothelial gene therapy: A minimalist yet mechanistically precise approach.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy remains the only cure for von Willebrand disease (VWD), but it is limited by the large von Willebrand factor (VWF) gene size. Variants affecting the VWF propeptide (VWFpp) impair multimerization, causing type 2A/IIC VWD. VWFpp serves as a pH-sensitive template for VWF multimer assembly, suggesting that in trans VWFpp supplementation may restore multimerization in VWF variants with defective propeptides. Co-expression of wild-type VWFpp with mutant full-length VWF in vitro led to modest yet consistent improvements in the VWF multimer profile across eight type 2A/IIC VWD-causing variants. Notably, variants with defect D2:D2 interface required lower levels of VWFpp for multimerization rescue, whereas those with intact D2:D2 interfaces exhibited a greater demand. Furthermore, a transgenic mouse model of type 2A/IIC VWD carrying the p.Tyr87Ser mutation was treated with an AAV9 vector encoding VWFpp under the control of endothelial-specific promoters. VWFpp administration remarkably restored VWF multimerization, increased VWF:CB levels from 15.8% ± 10.2% to 71.2% ± 12.7% for at least 16 weeks, corrected the bleeding tendency and improved platelet function. Both in vitro and in vivo findings demonstrate that in trans VWFpp supplementation can rectify defects in VWF multimerization caused by variants in VWFpp, offering a novel therapeutic strategy for type 2A/IIC VWD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.